Session 4: What are the strategic and technological manufacturing and supply chain advances required to enable commercial CAR-T cell therapies to scale beyond 20% of eligible patients?

CDMO CRO & Partnering,Clinical Development & Regulatory Strategy,Commercialisation & Market Access,Global Markets & International Development,Manufacturing CMC & Supply Chain

Academic & Clinical Researchers,Biotech,Clinicians,CMC & Supply Chain,Industry Associations & Foundations,Logistics & Distribution Partners,Patient Advocates & Organizations,Payers,Pharma,Regulators & Policy Makers,Service Providers (CDMOs CROs & Suppliers),Tools tech & equipment providers